Eli Lilly slashes price of diabetes and weight-loss drugs in Canada, Globe and Mail reports
ReutersDec 18, 2025 4:17 AM
Dec 17 (Reuters) - Eli Lilly LLY.N is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada, the Globe and Mail reported on Wednesday.
Reuters could not immediately verify the report.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Gold Price Hits New High: Has Bitcoin Fully Declined?
Gold prices surged over 70% in 2025, while Bitcoin fell over 5%. Will there be a chance for a comeback in the future?TradingKey
8 hours ago
US Q3 GDP Set for Release, Will US Stocks See a "Santa Claus Rally"?【The week ahead】
TradingKey - This week, global financial markets will enter "Christmas mode." Investors should focus on US GDP data, and Bank of Japan Governor Kazuo Ueda will deliver a speech, potentially offering clues on the interest rate trajectory for 2026.TradingKey
Mon, Dec 22
Rocket Lab Stock Analysis: Why Is Rocket Lab Stock Price Soaring? Is Now a Good Time To Buy?
TradingKey - Even though Rocket Lab's stock price has seen substantial gains from its previous levels, we believe that Rocket Lab still offers speculative value.TradingKey
Mon, Dec 22
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Tradingkey
